Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases.
BACKGROUND
Thrombolytic therapy reduces stroke size and disability by reperfusion and salvage of ischaemic penumbra. Emerging evidence suggests that retrieved penumbra may be the site of ongoing inflammatory pathology that includes extensive microglial activation. Microglial activation may be associated with excessive levels of tumour necrosis factor (TNF) and resultant neurotoxicity. Etanercept, a potent biologic TNF antagonist, reduces microglial activation in experimental models and has been therapeutically effective in models of brain and neuronal injury. Perispinal administration of etanercept, previously reported to be beneficial for the treatment of Alzheimer's disease, may facilitate delivery of etanercept into the brain.


OBJECTIVE
The objective of this report is to document the initial clinical response to perispinal etanercept in the first chronic stroke cohort so treated.


METHODS
Three consecutive patients with stable and persistent chronic neurological deficits due to strokes that had failed to resolve despite previous treatment and rehabilitation were evaluated at an outpatient clinic. They were treated off-label with perispinal etanercept as part of the clinic's practice of medicine.


RESULTS
All three patients had chronic hemiparesis, in addition to other stroke deficits. Their stroke distributions were right middle cerebral artery (MCA), brainstem (medulla) and left MCA. The two patients with MCA strokes had both received acute thrombolytic therapy. Each of the three patients was treated with an initial dose of perispinal etanercept 13, 35 and 36 months following their acute stroke, respectively. Significant clinical improvement following perispinal etanercept administration was observed in all patients. Onset of clinical response was evident within 10 minutes of perispinal injection in all patients. Improvements in hemiparesis, gait, hand function, hemi-sensory deficits, spatial perception, speech, cognition and behaviour were noted among the patients treated. Each patient received a second perispinal etanercept dose at 22-26 days after the first dose that was followed by additional clinical improvement.


CONCLUSIONS
Open-label administration of perispinal etanercept resulted in rapid neurological improvement in three consecutive patients with chronic neurological dysfunction due to strokes occurring 13-36 months earlier. These results suggest that stroke may result in chronic TNF-mediated pathophysiology that may be amenable to therapeutic intervention long after the acute event. Randomized clinical trials of perispinal etanercept for selected patients with chronic neurological dysfunction following stroke are indicated.
Institute for Neurological Research, a private medical group, inc., Los Angeles, California, USA. etmd@ucla.edu
Edward
E
Tobinick
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D001519:Behavior / Q000187:drug effects; D003071:Cognition / Q000187:drug effects; D000068800:Etanercept; D005684:Gait / Q000187:drug effects; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000627:therapeutic use*; D008297:Male; D008526:Medulla Oblongata / Q000473:pathology; D008875:Middle Aged; D020768:Middle Cerebral Artery / Q000473:pathology; D009043:Motor Activity / Q000187:drug effects; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology*; D010291:Paresis / Q000188:drug therapy / Q000209:etiology; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage* / Q000627:therapeutic use*; D012678:Sensation Disorders / Q000188:drug therapy / Q000209:etiology; D013028:Space Perception / Q000187:drug effects; D013060:Speech / Q000187:drug effects; D020521:Stroke / Q000150:complications* / Q000473:pathology; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
Exp Transl Stroke Med. 2010 Dec 20;2(1):22
21171972
Biomed Pharmacother. 2001 Jun;55(5):258-63
11428551
Stroke. 2006 Jul;37(7):1749-53
16763188
J Cereb Blood Flow Metab. 2000 Jan;20(1):53-65
10616793
Stroke. 1995 Dec;26(12):2219-21
7491639
BMC Neurol. 2008 Jul 21;8:27
18644112
Curr Alzheimer Res. 2007 Dec;4(5):550-2
18220520
Neurobiol Aging. 2010 Nov;31(11):1877-84
19070941
Curr Alzheimer Res. 2007 Sep;4(4):378-85
17908040
Expert Rev Neurother. 2010 Jun;10(6):985-1002
20518613
Can J Psychiatry. 2007 May;52(5):329-32
17542384
Joint Bone Spine. 2010 Jul;77(4):366-7
20478733
Respiration. 2010;80(3):212-9
20431280
Arch Phys Med Rehabil. 1995 Jan;76(1):27-32
7811170
Cell Signal. 2010 Jul;22(7):977-83
20096353
J Neuroimmunol. 1990 Dec;30(2-3):213-7
2229409
Eur J Neurosci. 2004 Dec;20(12):3387-96
15610171
Brain Res. 2003 Oct 31;989(1):1-8
14519505
Int Disabil Stud. 1990 Jul-Sep;12(3):119-22
2096120
Am J Roentgenol Radium Ther Nucl Med. 1957 Aug;78(2):195-212
13444513
BMC Res Notes. 2009 Feb 27;2:28
19284700
J Gerontol A Biol Sci Med Sci. 2007 Aug;62(8):844-50
17702875
J Alzheimers Dis. 2010;21(3):763-7
20693638
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9
9236950
Neuroimage. 2010 Jan 1;49(1):19-31
19716426
Drug Discov Today. 2009 Feb;14(3-4):168-77
19027875
Psychosomatics. 2010 Nov-Dec;51(6):474-9
21051678
Pharmacol Ther. 2010 Dec;128(3):519-48
20813131
MedGenMed. 2006 Feb 22;8(1):53
16915183
Acta Biomed. 2007;78 Suppl 1:84-98
17465327
Cerebrovasc Dis. 2005;20 Suppl 2:25-31
16327251
Cell Mol Neurobiol. 1998 Dec;18(6):621-38
9876870
J Nucl Med. 2010 Nov;51(11):1788-95
21051651
J Neurochem. 2010 Nov;115(4):921-9
20796174
J Neuroinflammation. 2008 Jan 09;5:2
18184433
J Gerontol A Biol Sci Med Sci. 2003 Dec;58(12):M1125-34
14684710
Eur J Neurosci. 2010 Jul;32(2):290-7
20646045
Stroke. 1999 May;30(5):1150-3
10229761
Cardiovasc Res. 2009 Sep 1;83(4):737-46
19457890
J Am Geriatr Soc. 2005 Apr;53(4):695-9
15817019
Brain Res. 2011 Jan 12;1368:239-47
20971085
Exp Neurol. 2009 Jan;215(1):29-40
18929562
CNS Drugs. 2009 Sep;23(9):713-25
19689163
J Neurosci. 2008 Feb 27;28(9):2221-30
18305255
Anesth Analg. 2011 Feb;112(2):454-9
21081778
Neuroscience. 1999;93(4):1449-64
10501470
Eur J Pain. 2009 Aug;13(7):673-81
18849175
Scand J Rehabil Med. 1987;19(1):25-30
3576138
J Neurosci Res. 2010 Feb 1;88(2):360-8
19746434
J Neuroinflammation. 2008 Jan 10;5:3
18186919
Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20518-22
21041647
Cerebrovasc Dis. 2005;20(3):154-63
16088110
J Pharmacol Exp Ther. 2006 Mar;316(3):1006-16
16303916